This new study, with the participation of Alessandro Cozzi-Lepri from University College of London, was published yesterday in the Vaccines journal.
The manuscript “Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV” analyses an observational cohort on the outcomes of COVID-19 mRNA vaccination in People living with HIV in a hospital in Rome, Italy.
The authors concluded that the humoral response against WD614G five months after first booster dose remained above population average levels, regardless of CD4 cell count. On the other hand, humoral response against Omicron BA.1 was below population average levels five months after first booster dose, regardless of CD4 cell count.
The authors also referred that: “Further evaluations on the effectiveness and waning of new mRNA bivalent vaccines against the current circulating omicron sub-lineages are warranted in order to establish more suitable booster vaccination strategies in case of endemic evolution of SARS-CoV-2 with increased pathogenicity.”
To read the full manuscript go to: https://doi.org/10.3390/vaccines11121739